Advances in structural and molecular neuroimaging in Alzheimer's disease

Longer life expectancies lead to increases in the prevalence of age‐associated illnesses. The number of Australians with dementia is predicted to rise, from 234 000 in 2009 to over 1 million by 2050, as a result of the increased prevalence of Alzheimer's disease (AD), the leading cause of demen...

Full description

Saved in:
Bibliographic Details
Published in:Medical journal of Australia 2011-02, Vol.194 (4), p.S20-S23
Main Authors: Ellis, Kathryn A, Rowe, Christopher C, Szoeke, Cassandra E I, Villemagne, Victor L, Ames, David, Chételat, Gaël, Martins, Ralph N, Masters, Colin L, Fripp, Jurgen, Acosta, Oscar, Raniga, Parnesh, Bourgeat, Pierrick T, Salvado, Olivier
Format: Article
Language:English
Subjects:
Aged
Alzheimer Disease - diagnosis
Alzheimer Disease - pathology
Amyloid beta-Peptides - analysis
Bioengineering
Biomarkers - analysis
Brain - pathology
Brain Chemistry
Diagnostic techniques and procedures
Humans
Life Sciences
Magnetic Resonance Imaging
Nervous system diseases
Positron-Emission Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Longer life expectancies lead to increases in the prevalence of age‐associated illnesses. The number of Australians with dementia is predicted to rise, from 234 000 in 2009 to over 1 million by 2050, as a result of the increased prevalence of Alzheimer's disease (AD), the leading cause of dementia in the elderly. Early diagnosis of AD will become more important as disease‐modifying therapies emerge within the next decade. Advances in molecular neuroimaging with amyloid‐β‐specific radioligands for positron emission tomography, aided by magnetic resonance imaging techniques, allow detection of AD years before symptoms of dementia develop. Longitudinal prospective studies, such as the Australian Imaging Biomarkers and Lifestyle (AIBL) study of ageing, will determine the sensitivity and specificity of these analysis techniques for diagnosing AD and predicting cognitive decline.
ISSN:0025-729X
1326-5377
DOI:10.5694/j.1326-5377.2011.tb02938.x